Clinical Trial Update: Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

This report summarizes a Phase 2 clinical trial evaluating outpatient and intermittent dosing of elranatamab for relapsed/refractory multiple myeloma, currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Elranatamab (elranatamab)

Snippet

Sponsor: Ontario Clinical Oncology Group (OCOG) | Conditions: Refractory Multiple Myeloma | Phase 2 | Status: RECRUITING